Oxford Covid-19 vaccine produces strong immune response in older adults

Oxford Covid-19 vaccine produces strong immune response in older adults

In a major development, it has emerged that a COVID-19 vaccine undergoing the third phase of a clinical trial in Pakistan has shown promising results, ARY NEWS reported on Friday.

The Sinopharm vaccine requires two doses per individual for efficacy.

That follows findings in older participants unveiled last month and data in July that showed the vaccine generated robust immune responses in adults aged 18 to 55.

It found that the vaccine caused few side effects, was better tolerated in older adults than in younger adults, and produced a similar immune response across age groups.

Many who have been inoculated in China are not formal participants in drugmakers' trials and are said to have done so voluntarily.

Earlier in the week U.S. biotech firm Moderna released data suggesting its vaccine is nearly almost 95% effective.

Experts have always been asking Pfizer and Moderna the demographics of their participants but there are no reports about it until now.

"We are relying on guidance from the CDC and the government's Operation Warp Speed initiative to finalize plans to safely administer COVID-19 vaccines to our frontline staff who choose to receive it when it becomes available".

Many other airports and airlines are also learnt to be preparing for vaccine transportation - possibly the largest ever air cargo opportunity so far; comments from them were awaited.

Andrew Pollard, director of the Oxford Vaccine Group, said however that it was still too early to know the level of effectiveness of the drug he develops with the British pharmacist and said: "We have not yet reached that point".

"We're still waiting to get to the point where we can do the analysis to just work out how well the vaccine can protect people, and we're getting ever closer to that", he told journalists.

The researchers from The University of Oxford and AstraZeneca began working on the vaccine in January and they started their human clinical trials in April.

Sinovac is already pushing ahead with late-stage trials, although one phase 3 trial of its vaccine was stopped in Brazil this month after reports of a serious safety concern, with one report stating a death is involved but that it was not in the vaccine arm.

Availability of the vaccine in India will be subject to approval by domestic regulators, and the Indian government agreeing to purchase them.